A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors

Aung Naing, Justin F. Gainor, Hans Gelderblom, Patrick M. Forde, Marcus O. Butler, Chia Chi Lin, Sunil Sharma, Maria Ochoa De Olza, Andrea Varga, Matthew Taylor, Jan H.M. Schellens, Hongqian Wu, Haiying Sun, Antonio P. Silva, Jason Faris, Jennifer Mataraza, Scott Cameron, Todd M. Bauer

    Research output: Contribution to journalArticlepeer-review

    22 Scopus citations

    Fingerprint

    Dive into the research topics of 'A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors'. Together they form a unique fingerprint.

    Medicine & Life Sciences